The rapidly changing healthcare environment offers an abundance of opportunities for companies that are poised and ready to adapt to evolving regulatory requirements and unique client needs. Seizing opportunities should be done in a sustainable and responsible manner to ensure that Mediclinic, as a good corporate citizen, is in the long term able to maintain its positive impact not only on its clients, but also on the industry, the planet, and on its employees, partners and surrounding communities.

Mediclinic’s track record on delivering growth and creating long-term value in across its divisions in Switzerland, Southern Africa and the United Arab Emirates is testament to its strategy of being a long-term player and delivering a sustainable business. While growth, profitability and creating shareholder value are certainly major strategic drivers, this cannot be achieved unless the Group offers efficient, effective, appropriate and evidence-based clinical services to its patients; follows ethical business practices; values its employees by following fair labour practices and offering competitive remuneration, training and development opportunities; respects the communities within which the Group operates and contributes to the well-being of society; and carefully manages its impact on the environment by focusing on its carbon footprint, use of energy and water resources and waste management.

Through the Group’s sustainability efforts Mediclinic believes that it will:

  • maintain its business integrity;
  • continue creating shareholder value and growing the business;
  • offer improved access to capital by providing a responsible investment proposition;
  • effectively manage its risks;
  • increase its ability to attract and retain employees;
  • effectively manage and minimise its impact on the environment; and
  • maintain and improve the confidence, trust and respect of its stakeholders.

The Group Sustainable Development Policy, Group Environmental Policy and Code of Business Conduct and Ethics, which are reviewed annually, codify Mediclinic’s commitment to conducting business responsibly.

The following material sustainability issues have been identified and are addressed in the sustainable development report published annually and available below: (a) to minimise the Company’s environmental impact; (b) to be the partner of choice that all our stakeholders trust; and (c) to strengthen our corporate culture to remain an ethical and responsible corporate citizen.

Broad-based Black Economic Empowerment

The Group’s subsidiaries in South Africa, including Mediclinic Southern Africa, form an integral part of the political, social and economic community in this geography and are committed to sustainable transformation.

Our Southern Africa division has assigned priority resources and time to implement a transformation strategy that encompasses diversity and inclusion and is dedicated to delivering transformational benefits to the organisation beyond compliance requirements. It has therefore aligned its efforts to the Group values and to the national priority for transformation in a transparent and deliberate manner.

Practical contributions are led by the divisional executive committee, with transformation champions across the business.

Diversity and inclusion fuel the division’s performance in other areas of broad-based black economic empowerment ('B-BBEE'), such as ownership and CSI. This focus also drives its approach to enhance access to quality healthcare and to collaborate with other stakeholders to achievethis goal.

Supply Chain Management

In order to deliver our services, we are dependent on a large and diverse range of suppliers that form an integral part of the Group’s ability to provide quality care. We believe in building long-term relationships with suitable suppliers and establishing a relationship of mutual trust and respect. The Group relies on its suppliers to deliver products and services of the highest quality in line with Mediclinic’s standards. The Group Supply Chain Risk Management Policy sets out how supply chain risks and related aspects are considered.

Modern Slavery

Mediclinic does not tolerate any form of human rights violation and is committed to ensuring that no form of slavery or human trafficking occurs in human resources, the supply chain or in any other part of the business.

For each financial year, the Board issues a statement in terms of Section 54 of the United Kingdom Modern Slavery Act 2015, reporting on the steps taken during the year to prevent modern slavery in the workplace.

Marlene de Beer
Group Corporate Governance and Legal Advisor